NCT03880422Recruiting
Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nutrition and exercise advice for prostate cancer patients on androgen deprivation therapy may help to reduce obese frailty and change the levels of myokines in blood.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 1 Mar 2019
- Start date
- 2 May 2019
- Primary completion date
- 2 May 2029
- Lead sponsor
- Roswell Park Cancer Institute
- Diseases
- Prostate cancer, Obesity
- NCT number
- NCT03880422
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 2 May 2019 to the primary completion date, 2 May 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known clinically significant severe chronic obstructive pulmonary disease (COPD), ischemic heart disease, congestive heart failure, and/or significant cardiac arrhythmias
- Limiting orthopedic, musculoskeletal or psychological conditions (clinician discretion)
- Any condition contraindicating additional blood collection beyond standard of care
- Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study intervention
Other
- Overall medical frailty (clinician discretion)
- Unwilling or unable to follow protocol requirements
Who the study is looking for
- Biopsy-confirmed prostate adenocarcinoma of any stage/grade
- Prescribed or already receiving continuous ADT for \< 5 years
- Hemoglobin \> 11 g/dL
- Creatinine \< 1.5 x upper limit of normal (ULN), AST or ALT \<2 x ULN within 6 months prior to enrollment
- Liver function tests \< 2 x ULN
- Able to walk unassisted at least 100 meters (200 steps) or ECOG \<= 1
- No contraindications to any aspect of participation, including aerobic exercise
- Participant must be able to read, write, and understand the English language and be able to provide written consent
- Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Roswell Park Cancer Institute Coordinator of this site? Confirm its status | Buffalo | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.